Clinical Trial Update: Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL [Phase 2]

View source ↗

Summary

Phase 2 trial update for chemoimmunotherapy in relapsed/refractory ALK-positive anaplastic large cell lymphoma; the study is currently active but not recruiting…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Large Cell Lymphoma

Snippet

Sponsor: New York Medical College | Conditions: Anaplastic Large Cell Lymphoma, ALK-Positive | Phase 2 | Status: ACTIVE_NOT_RECRUITING